Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Prostate Carcinoma
Explore 108 assets in Prostate Carcinoma →Floatz Rating
CC44/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
protein_peptide
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
29Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04633252CT.gov A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap (this asset) | National Cancer Institute (NCI) | P1/2 | CC · 44 |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Prednisone | Mayo Clinic | P4 | BBB |
| Enzalutamide | Pfizer | P4 | BBB |
| Degarelix | Baptist Health South Florida | P3 | BBB |
| Abiraterone | Mayo Clinic | P4 | BBB |
| Docetaxel | Alliance for Clinical Trials in Oncology | P3 | BB |
| Goserelin | Mayo Clinic | P3 | BB |
| Fludeoxyglucose | Jonsson Comprehensive Cancer Center | P2/3 | BB |
+41 more in the Prostate Carcinoma cohort
Other indications for Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Oropharyngeal Carcinoma | — | P2 | B · 57 |
| Reproductive System Cancer | — | P1/2 | CCC · 55 |
| Triple-Negative Breast Carcinoma | — | P2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap in Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunotherapic-bifunctional-fusion-protein-comprised-of-a-fully-human-igg1-monoclonal-antibody-avelumab-against-human-programmed-death-ligand-1-pd-l1-fused-to-the-soluble-extracellular-domain-of-transforming-growth-factor-beta-tgf-beta-receptor-ii-which-acts-as-a-tgf-beta-trap-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →